Efficacy and feasibility of vein of Marshall ethanol infusion during persistent atrial fibrillation ablation: A systematic review and meta‐analysis
Clinical Cardiology · 2024
DOI: 10.1002/clc.24178 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Wei-Li Ge und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Catheter ablation (CA) is currently used to treat persistent atrial fibrillation (PeAF). However, its effectiveness is limited. This study aimed to estimate the effectiveness of the vein of Marshall absolute ethanol injection (VOM‐EI) for PeAF ablation. Hypothesis Adjunctive vein of Marshall ethanol injection (VOM‐EI) strategies are more effective than conventional catheter ablation (CA) and have similar safety outcomes.
Methods
We extensively searched the literature for studies evaluating the effectiveness and safety of VOM‐EI + CA compared with CA alone. The primary endpoint was the rate of acute bidirectional block of the isthmus of the mitral annulus (MIBB). The secondary endpoints were atrial fibrillation (AF) or atrial tachycardia (AT) recurrence over 30 seconds after a 3‐month blanking period. Weighted pooled risk ratios (RRs) and corresponding 95% confidence intervals (CIs) were calculated using a random effects model.
Results
Based on the selection criteria, nine studies were included in this systematic review, including patients with AF ( n = 2508), persistent AF ( n = 1829), perimitral flutter ( n = 103), and perimitral AT ( n = 165). There were 1028 patients in the VOM‐EI + CA group and 1605 in the CA alone group. The VOM‐EI + CA group showed a lower rate of AF/AT relapse (RR = 0.70; 95% CI = 0.53–0.91; p = .008) and a higher rate of acute MIBB (RR = 1.29; 95% CI = 1.11–1.50; p = .0007) than the CA alone group.
Conclusion
Our meta‐analysis revealed that adjunctive VOM‐EI strategies are more effective than conventional CA and have similar safety outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China.
- Department of Cardiology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Zhejiang, China.
- Evidence-Based Medicine Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, China.
- Department of Urology, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Enze Hospital, Taizhou Enze Medical Center (Group), Affilitated to Hangzhou Medical College, Taizhou, Zhejiang, Chin…
- Key Laboratory of Evidence-Based Radiology of Taizhou, Linhai, Zhejiang, China.
- Department of Cardiology, Shandong Provincial Qianfoshan Hospital, Jinan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ge, W. L., Li, T., Lu, Y. F., Jiang, J. J., Tung, T. H., & Yan, S. H. (2024). Efficacy and feasibility of vein of Marshall ethanol infusion during persistent atrial fibrillation ablation: A systematic review and meta‐analysis. Clinical Cardiology. https://doi.org/10.1002/clc.24178
Vancouver
Ge WL, Li T, Lu YF, Jiang JJ, Tung TH, Yan SH. Efficacy and feasibility of vein of Marshall ethanol infusion during persistent atrial fibrillation ablation: A systematic review and meta‐analysis. Clinical Cardiology. 2024. doi:10.1002/clc.24178
BibTeX
@article{Ge2024,
author = {Ge, Wei-Li and Li, Tao and Lu, Yi-Fei and Jiang, Jian-Jun and Tung, Tao-Hsin and Yan, Su-Hua},
title = {Efficacy and feasibility of vein of Marshall ethanol infusion during persistent atrial fibrillation ablation: A systematic review and meta‐analysis},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.24178}
}
EUVIMED